Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : QLGN save search
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
MRZM | $0.095 1031.22% 2.2K
|
Information
|
| O: 0.0%
H: 72.73%
C: 72.73%
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -4.91%
H: 3.23%
C: -3.29%
for commercialization therapeutics agreement
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -2.03%
H: 2.35%
C: -2.76%
association direct cancer research meeting
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
Published: 2023-11-14 (Crawled : 22:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 4.76%
H: 0.0%
C: -4.55%
update therapeutics
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-11-07 (Crawled : 14:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 2.86%
H: 4.17%
C: 0.38%
qn-302 tumors treatment trial therapeutics
Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer
Published: 2023-10-23 (Crawled : 12:30) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -6.23%
breast cancer platform
Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023
Published: 2023-09-27 (Crawled : 14:30) - biospace.com/
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: -1.9%
qn-302 cancer pancreatic therapeutics
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-17 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: -1.83%
qn-302 tumors treatment therapeutics
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023
Published: 2023-08-15 (Crawled : 12:20) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -1.9%
H: 6.8%
C: 6.14%
update financial results
Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
Published: 2023-08-01 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 10.62%
H: 0.8%
C: -9.6%
qn-302 fda tumors treatment clearance trial therapeutics
Qualigen Therapeutics Divests FastPack® Diagnostics Business
Published: 2023-07-24 (Crawled : 12:20) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 0.48%
H: 0.0%
C: -0.48%
fastpack business diagnostics therapeutics
4 Singapore REITs That Undertook Acquisitions to Boost Their DPUs – The Smart Investor
Published: 2023-06-13 (Crawled : 00:00) - spacfeed.com
CFFS | $10.84 -0.27% 200
|
n/a
|
| O: -0.19%
H: 0.77%
C: 0.0%
FATP | $10.915 -0.14% 8.2K
|
n/a
|
| O: -0.56%
H: 0.28%
C: 0.09%
CZFS 4 | $44.85 3.65% 3.52% 7.3K
|
Finance and Insurance
|
| O: 0.0%
H: 2.52%
C: 0.94%
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -1.5%
H: 3.54%
C: -1.5%
acquisitions smart
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Published: 2023-06-05 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 2.26%
H: 6.67%
C: 1.9%
meeting platform
Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending March 31, 2023
Published: 2023-05-16 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: -4.9%
H: 3.86%
C: 2.05%
update financial results
Qualigen Therapeutics, Inc. Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update
Published: 2023-05-02 (Crawled : 21:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 2.01%
H: 0.0%
C: -7.83%
update financial results
Qualigen Therapeutics’ Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Published: 2023-05-02 (Crawled : 12:20) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 5.15%
H: 7.14%
C: 2.03%
meeting program
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
Published: 2023-04-21 (Crawled : 22:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
| Email alert
Add to watchlist
nasdaq
Qualigen Therapeutics Announces Four Posters on QN-302 Presented at the American Association of Cancer Research (AACR) 2023 Annual Meeting in Orlando, FL
Published: 2023-04-18 (Crawled : 13:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 0.5%
H: 3.16%
C: -5.95%
qn-302 association cancer research meeting therapeutics
Qualigen Therapeutics Presents Data On QN-247 in Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, FL
Published: 2023-04-18 (Crawled : 12:00) - biospace.com/
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 0.5%
H: 3.16%
C: -5.95%
qn-247 breast association cancer research meeting therapeutics negative
Composition of Matter Patent for QN-302 Granted by United States Patent and Trademark Office
Published: 2023-03-21 (Crawled : 13:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 22.45%
H: 14.17%
C: -5.0%
qn-302 patent granted
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.